|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,632.00 GBX | -1.19% |
|
+3.16% | -1.15% |
| 04:36pm | Stockholm stocks retreat on Tuesday, OMXS30 index sheds 1.2 percent | FW |
| 03:30pm | What Bundibugyo Ebola vaccines and treatments are under development | RE |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 285,479 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -0.81% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 305,075 | 298,147 | 290,743 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -1.96% | -2.27% | -2.48% |
| P/E ratio | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 23.3x | 20.2x | 17.5x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 5.38x | 4.63x | 3.78x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.1x | 1.3x | 1.1x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 4.51x | 4.25x | 3.99x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.82x | 4.44x | 4.06x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 13.7x | 12.2x | 10.9x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 14.4x | 12.7x | 11.3x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 30.5x | 22.4x | 19.8x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.28% | 4.46% | 5.05% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.337 | 3.524 | 3.659 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 1.81% | 1.91% | 1.99% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.914 | 9.101 | 10.51 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 42.2% | 38.7% | 34.8% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,339 | 67,139 | 71,535 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,244 | 24,386 | 26,561 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,248 | 23,529 | 25,792 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 12,406 | 14,066 | 15,979 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,596 | 12,668 | 5,264 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 184.06 | 184.06 | 184.06 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,550,996 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 06/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.32x | 4.83x | 13.75x | 1.81% | 286B | |
| 33.62x | 12.22x | 25.16x | 0.59% | 1,025B | |
| 24.81x | 5.72x | 15.56x | 2.3% | 559B | |
| 27.31x | 6.66x | 13.61x | 3.08% | 394B | |
| 17.31x | 4.28x | 10.51x | 3.11% | 324B | |
| 53.32x | 4.96x | 20.16x | 2.8% | 295B | |
| 20.51x | 5.3x | 12.89x | 3.08% | 270B | |
| 12.03x | 4.53x | 9.26x | 4.17% | 186B | |
| 22.48x | 6.03x | 10.53x | 2.92% | 187B | |
| -45.84x | 5.54x | 31.24x | 2.53% | 159B | |
| Average | 18.89x | 6.01x | 16.27x | 2.64% | 368.53B | |
| Weighted average by Cap. | 24.91x | 7.29x | 17.71x | 2.17% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition